dysautonomia
Yoon Hang Kim, MD, MPHBoard-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information here should not be used to diagnose or treat any condition without the guidance of a qualified, licensed clinician familiar
ldn
LDN Fillers: What’s Available, What Works, and What to Avoid A Clinician’s Evidence-Based Guide to Compounded LDN Excipients Yoon Hang Kim, MD, MPH | Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Direct Integrative Care Published June 2026 Introduction: Why LDN Fillers Matter More Than You Think Low
ldn
CLINICAL REFERENCE NOTE Low-Dose Naltrexone (LDN) in Solid Organ Transplant Recipients on Chronic Immunosuppression Prepared by Yoon Hang Kim, MD, MPH | Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Reviewed: May 2026 | Internal clinical reference — not patient-facing Bottom line The concern is pharmacodynamic and entirely theoretical. There are no
ldn
by Yoon Hang Kim MD Question: Can prednisone or other medications sometimes trigger a return of inflammatory pain symptoms in people who had previously been doing well on low-dose naltrexone (LDN)? For example, if someone had several months of significant pain relief on LDN, then developed an infection and was
ldn
Q: I'm trying to determine if the joint pain I am having can be from the LDN. I'm currently at 3 mg and my feet and thumbs have been hurting more and more. Thinking back I'm beginning to think it started increasing when I
ldn
Low-Dose Naltrexone and Gastrointestinal Health Mechanisms, Clinical Evidence, and Integrative Applications Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine Integrative & Functional Medicine Physician Abstract Low-dose naltrexone (LDN), administered at doses of approximately 0.5 to 4.5 mg daily, has emerged as a versatile off-label therapy with proposed
ldn
Start-Low-Go-Slow Protocols for MCAS, ME/CFS, and Autoimmune Disease Yoon Hang “John” Kim, MD, MPH, FAAMA Board-Certified Preventive Medicine | Integrative & Functional Medicine | LDN Research Trust Presenter The short version If you’ve been told LDN will make you better but every dose so far has made you worse, you
LDN Primer
Dr. Kim's LDN Primer Book which covers basics of LDN is now available in Amazon - https://www.amazon.com/dp/B0GZ9R4667/ref=sr_1_1?crid=Y99J3Z8DLKY2&dib=eyJ2IjoiMSJ9.Kq_wzqE15_OGnVOgkdQHbQdwZK32CtfPr6H9aL8NtC2JdRuLQJkskth03cPcjIrlnpNzzTw6NqVAdjbFJvOflQ.owU6k5lJ4jkFwPod1eq9pIC126Fde8sml1nlDi_ameE&dib_tag=se&keywords=Low+Dose+Naltrexone+%28LDN%29+Primer%
hormone
CLINICAL EDUCATION SERIES Low-Dose Naltrexone and Hormonal Health: What the Evidence Actually Shows Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician www.directintegrativecare.com ABSTRACT Background: Low-dose naltrexone (LDN), administered at 1.5–4.5 mg nightly, is increasingly used off-label in integrative medicine
CIRS
By Yoon Hang Kim, MD, MPH | Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Chronic illness patients — especially those navigating mold illness, Lyme disease, autoimmune conditions, or post-infectious syndromes — frequently encounter two acronyms that are both confusing and critically important: CIRS and MCAS. These conditions share a great deal
Integrative Oncology
Cholangiocarcinoma (CCA) is an aggressive malignancy arising from the epithelial lining of the biliary tree. The disease is traditionally divided by anatomic origin into three subtypes: intrahepatic (iCCA, arising from small bile ducts within the liver), perihilar (pCCA, at the hepatic duct confluence), and distal (dCCA, within the extrahepatic bile
ldn
1. LDN is a Tool — Not a Cure-All LDN can be highly beneficial, especially for immune modulation, but it is not sufficient as a standalone therapy in most complex chronic illnesses. It should be viewed as a cornerstone, not the entire structure. 2. Individual Variability is the Rule Patient responses